Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Wu, ERDEM; Tsuboi, Masahiro; He, Jie; John, Thomas; Grohe, Christian; Majem, Margarita; Goldman, Jonathan; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu-Vinh; Lu, Shun; Lee, Kye-Young; Akewanlop, Charuwan; Yu, Chong-Jen; de Marinis, Filippo; Bonanno, Laura; Domine, Manuel; Shepherd, Frances; Zeng, Lingmin; Hodge, Rachel; Atasoy, Ajlan; Rukazenkov, Yuri; Herbst, Roy

doi:10.1056/nejmoa2027071

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

Wu Y., Tsuboi M., He J., John T., Grohe C., Majem M., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.383, sa.18, ss.1711-1723, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 383 Sayı: 18
Basım Tarihi: 2020
Doi Numarası: 10.1056/nejmoa2027071
Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Sayfa Sayıları: ss.1711-1723
Bursa Uludağ Üniversitesi Adresli: Hayır

Özet

BackgroundOsimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.